CompletedNot Applicable

Fungal Biomarkers to Reduce Duration of Empirical Antifungal Therapy: a Randomized Comparative Study (STAFE)

France110 participantsStarted 2014-07

Plain-language summary

The investigators hypothesized that the use of biomarkers of invasive fungal infections would increase the percentage of early discontinuation of empirical antifungal therapy and thus reduce the duration of treatment in ICU patients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age \> or = 18 years * Patients requiring empiric antifungal therapy the first time in the ICU * Predictable duration of hospitalization in the ICU ≥ 6 days Exclusion Criteria: * Neutropenia (WBC \<1000 or neutrophils \<500/mm3) * Immunosuppressive therapy (chemotherapy within 3 months prior to the ICU admission, solid organ graft under immunosuppressive therapy) * invasive fungal infection documented in the three previous months * Antifungal treatment in the three previous months * Pregnant or lactating women

What they're measuring

percentage of early discontinuation of empiric antifungal therapy

Timeframe: 7 days

Trial details

NCT IDNCT02154178

SponsorUniversity Hospital, Lille

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-10

View on ClinicalTrials.gov More Fungal Infection trials